Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Madrigal Pharmaceuticals (MDGL) announced on Friday an exclusive global license agreement with Pfizer (PFE) for ervogastat, ...

However, there's one potentially lucrative growth opportunity that Pfizer's focusing on that could change things and ...

Pfizer is penning a cancer discovery pact with Cartography Biosciences that could max out at $865 million biobucks. | Pfizer ...

While I believe Pfizer will rebound eventually, it will take some time to do so, and it may not occur in 2026. In the ...

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...

More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers ...

Bayer's Monsanto sued COVID-19 vaccine makers Pfizer , BioNTech and Moderna in Delaware federal court on Tuesday for ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

An analysis of safety data suggests that Abrysvo, the Pfizer respiratory syncytial virus (RSV) RSVpreF vaccine, does not ...

Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth.